Literature DB >> 16642318

Patients' attitudes on how to deal with the risk of future stone recurrences.

Hans-Göran Tiselius1.   

Abstract

One hundred consecutive patients referred for active stone removal responded to a number of questions regarding their attitude to metabolic risk evaluation and recurrence prevention. Of the 74 men and 26 women all but one were interested in the cause of their disease. While 95% of the patients were motivated to change their dietary habits, only 71% were interested in pharmacological treatment. Collection of 24-h urine for risk evaluation in one or five fractions was acceptable to 94 and 84% of the patients, respectively. Only 79% wanted to collect urine during more than one 24-h period. Given the option of a recurrence prevention programme or active stone removal when or if a stone appeared, approximately half of our patients (52%) chose the first, and about one-third (29%) of them chose the second alternative, whereas as many as 19% of the patients did not express any opinion. A programme for regular follow-up in order to detect new stones early was appreciated by only 81 patients. These results show that biochemical risk evaluation and recurrence prevention is generally met with a positive attitude by most patients and that medical recurrence prevention appears to be appreciated by more than half of the patients.

Entities:  

Mesh:

Year:  2006        PMID: 16642318     DOI: 10.1007/s00240-006-0056-2

Source DB:  PubMed          Journal:  Urol Res        ISSN: 0300-5623


  26 in total

Review 1.  Guidelines on urolithiasis.

Authors:  H G Tiselius; D Ackermann; P Alken; C Buck; P Conort; M Gallucci
Journal:  Eur Urol       Date:  2001-10       Impact factor: 20.096

Review 2.  The medical aspects of urolithiasis: an overview.

Authors:  L H Smith
Journal:  J Urol       Date:  1989-03       Impact factor: 7.450

Review 3.  Physico-chemical aspects of calcium stone formation.

Authors:  J M Baumann
Journal:  Urol Res       Date:  1990

4.  Repeated urine analysis in patients with calcium stone disease.

Authors:  H Bek-Jensen; H G Tiselius
Journal:  Eur Urol       Date:  1998       Impact factor: 20.096

Review 5.  Metabolic evaluation of patients with stone disease.

Authors:  H G Tiselius
Journal:  Urol Int       Date:  1997       Impact factor: 2.089

6.  Activity products in stone-forming and non-stone-forming urine.

Authors:  W G Robertson; M Peacock; B E Nordin
Journal:  Clin Sci       Date:  1968-06       Impact factor: 6.124

7.  Value of repeated analyses of 24-hour urine in recurrent calcium urolithiasis.

Authors:  K Höbarth; J Hofbauer; N Szabo
Journal:  Urology       Date:  1994-07       Impact factor: 2.649

8.  Thiazide treatment for calcium urolithiasis in patients with idiopathic hypercalciuria.

Authors:  M Ohkawa; S Tokunaga; T Nakashima; M Orito; H Hisazumi
Journal:  Br J Urol       Date:  1992-06

9.  Recurrent urolithiasis: a general-practice study of risk factors and clinical consequences.

Authors:  E Laerum
Journal:  Scand J Urol Nephrol       Date:  1984

10.  Chlorthalidone reduces calcium oxalate calculous recurrence but magnesium hydroxide does not.

Authors:  B Ettinger; J T Citron; B Livermore; L I Dolman
Journal:  J Urol       Date:  1988-04       Impact factor: 7.450

View more
  4 in total

1.  Effect of diet orange soda on urinary lithogenicity.

Authors:  Nicola T Sumorok; John R Asplin; Brian H Eisner; Marshall L Stoller; David S Goldfarb
Journal:  Urol Res       Date:  2011-08-20

Review 2.  Dietary therapy for patients with hypocitraturic nephrolithiasis.

Authors:  Michael P Kurtz; Brian H Eisner
Journal:  Nat Rev Urol       Date:  2011-02-15       Impact factor: 14.432

3.  Relevance of the BONN Risk Index for metabolic monitoring of patients with calcium oxalate urolithiasis: a clinical application study of the Urolizer.

Authors:  Wolfgang Berg; Robin Bechler; Claudia Haas; Norbert Laube
Journal:  Urol Res       Date:  2009-02-10

4.  Dipstick Spot urine pH does not accurately represent 24 hour urine PH measured by an electrode.

Authors:  Mohamed Omar; Carl Sarkissian; Li Jianbo; Juan Calle; Manoj Monga
Journal:  Int Braz J Urol       Date:  2016 May-Jun       Impact factor: 1.541

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.